An online campaign has been launched against a US drug maker accused of inflating prices of an anti-HIV drug by thousands of dollars. And it turns out the company doesn’t even own the patent for the treatment.
An online campaign has been launched against a US drug maker accused of inflating prices of an anti-HIV drug by thousands of dollars. And it turns out the company doesn’t even own the patent for the treatment.